PF-08046037
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-08046037, covering 2026-04-23 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies [Phase 1]